Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019361 | 0.83 | CYP2C19 (0.64) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL8188457 | 0.83 | CYP2C19 (0.64) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL7362447 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNAFOLH1 | |
| SCHEMBL13567542 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL6318417 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL23513631 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNAFOLH1 | |
| SCHEMBL7362451 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNAFOLH1 | |
| SCHEMBL16310142 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL28796343 | 0.81 | CYP2C19 (0.60) | CYP2C19RAB9ACTSCLMNASLC1A3 | |
| SCHEMBL7223221 | 0.80 | CYP2C19 (0.58) | CYP2C19RAB9ACTSCLMNASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | CYP2C19 153/4885RAB9A 1435/4885CTSC 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.